A biologic agent known as tildrakizumab has demonstrated a positive outcome in two Phase III trials conducted by Harvard Medical School’s Beth Israel Deaconess Medical Centre (BIDMC) to treat patients with plaque psoriasis.

Tildrakizumab is based on the body’s natural molecules such as antibodies and targets a specific pathway.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The results showed that tildrakizumab is efficacious and well-tolerated in moderate-to-severe chronic plaque psoriasis patients.

The parallel, double-blind, randomised, controlled Phase III trials evaluated the ability of 100mg or 200mg of tildrakizumab to clear up and control the disease in more than 1,800 patients.

The reSURFACE 1 and reSURFACE 2 trials were performed at 250 sites in Austria, Australia, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, the UK and the US.

"The breakthrough here is that we have continued to refine our treatments to those that are likely to be most effective against psoriasis but less likely to affect other important pathways at the same time."

BIDMC Harvard Medical Faculty Physicians (HMFP) president and CEO Alexa Kimball said: “In these two trials, we tested whether this new, very targeted approach to a selected part of the inflammatory pathway would be effective in treating psoriasis, and it was, dramatically so.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The data showed that 65% of the patients in the trial with 30% of their body covered with psoriasis, experienced a complete skin clearance or had almost clear skin at the end of the treatment period.

The clearance represented a 75% improvement when compared to 10% by placebo, measured using the standard psoriasis area severity index (PASI).

Kimball further added: “The breakthrough here is that we have continued to refine our treatments to those that are likely to be most effective against psoriasis but less likely to affect other important pathways at the same time.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact